Why Is BioMarin Stock Trading Higher On Thursday?
1. Q4 adjusted EPS rose to 92 cents from 49, beating consensus. Strong earnings beat expectations. 2. Sales reached $747.31M versus $713.44M consensus, with 16% revenue growth. Solid top‐line performance. 3. Guidance for fiscal 2025 EPS of $4.20-$4.40 exceeds consensus. Positive outlook for future growth. 4. Voxzogo drives global demand while enzyme therapies maintain steady revenue. Competition from Ascendis noted. 5. Analyst upgrades and raised price targets boost sentiment. Stock already up over 3% on strong results.